Mark M. Mendez

Davis Polk advised the representative of the underwriters in connection with an SEC-registered offering by TimkenSteel Corporation of $75 million aggregate principal amount of its 6.00%…

Davis Polk is advising Anacor Pharmaceuticals, Inc. on its approximately $5.2 billion acquisition by Pfizer Inc. The closing of the transaction, which is expected in the third quarter…

Davis Polk advised the representative of the initial purchasers in connection with a Rule 144A offering by Knowles Corporation of $150 million aggregate principal amount of its 3.25%…

Davis Polk advised Anacor Pharmaceuticals, Inc. in connection with its offering of $287.5 million aggregate principal amount of its 2.00% convertible senior notes due 2023 to qualified…

Davis Polk is advising Atairos on its $250 million investment in Groupon. Under the terms of the investment, Atairos is purchasing $250 million in aggregate principal amount of 3.25%…

Davis Polk acted as counsel to an affiliate of the counterparty in connection with the execution of a forward sale agreement with Regency Centers Corporation relating to 3,100,000 shares of…

Davis Polk is advising Markit on its all-share merger of equals with IHS valued at more than $13 billion. The transaction is expected to close in the second half of 2016, subject to…

Davis Polk advised the joint book-running managers on an SEC-registered offering by KKR & Co. L.P. of 13,800,000 6.75% Series A preferred units, which includes the full exercise of the…

Davis Polk advised the dealer manager in connection with a fixed-dollar, uncollared accelerated share repurchase transaction it entered into with Ulta Salon, Cosmetics & Fragrance, Inc…

Davis Polk advised the counterparty in connection with an accelerated share repurchase transaction entered into between the counterparty and Pfizer Inc. (“Pfizer”), pursuant to which Pfizer…